Key points are not available for this paper at this time.
Introduction and Objective: India's pharmaceutical industry faces challenges in meeting USFDA quality standards, impacting exports and reputation. This review examines the causes of non-compliance and proposes strategies to enhance compliance, predicting fu-ture trends. Methods: This study conducts an analysis of USFDA warning letters to Indian manufacturers, an assessment of non-compliance issues, and an exploration of technological advancements in compliance, such as automation and AI. Results: The study reveals a rise in non-compliance incidents, emphasizing the need for a ro-bust quality culture, updated regulatory knowledge, and implementation of advanced technol-ogies to improve compliance. Conclusion: To maintain global competitiveness, India's pharma industry must adopt compre-hensive strategies, leverage technology, and prepare proactively for regulatory changes. Future compliance will rely on remote auditing and real-time monitoring.
Kamal et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: